Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China
- 5 September 2019
- journal article
- research article
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 15 (6) , 595-600
Abstract
Interferon alpha (IFN-α) is a preferred therapy for antiviral treatment of children with chronic hepatitis B (CHB) aged > 1 year currently. Peginterferon alpha-2a (Peg-IFN α-2a) is a recommended international guideline for treatment of CHB children, which is limited to children aged > 3 years. But the exact efficacy and safety of IFN-α and Peg-IFN α-2a for treating CHB are not sufficient.Keywords
This publication has 23 references indexed in Scilit:
- Chronic hepatitis B in children and adolescentsJournal of Hepatology, 2012
- Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or CHepatology, 2011
- Treatment of Children With Chronic Hepatitis B Virus Infection in the United StatesHepatology, 2010
- Clearance of Hepatitis B Surface Antigen and Risk of Hepatocellular Carcinoma in A Cohort Chronically Infected With Hepatitis B VirusHepatology, 2010
- Long-Term Outcome in Children with Chronic Hepatitis B: A 24-Year Observation PeriodClinical Infectious Diseases, 2007
- Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal studyHepatology, 2006
- Long-Term Outcome after Hepatitis B Surface Antigen Seroclearance in Patients with Chronic Hepatitis BThe American Journal of Medicine, 2006
- Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2005
- Long‐Term Follow‐up of Chronic Hepatitis B Virus Infection in Children of Different Ethnic OriginsThe Journal of Infectious Diseases, 2002
- Interferon alfa therapy for chronic hepatitis B in children: A multinational randomized controlled trial☆Gastroenterology, 1998